Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 12, Issue 3, 2000, Pages 255-266

  Chesney, Margaret A ^a   Ickovics, J R ^b   Chambers, D B ^a   Gifford, A L ^c   Neidig, J ^d   Zwickl, B ^e   Wu, A W ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d Immunology and Medical Genetics   (United States)

^e INDIANA UNIVERSITY   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADULT; AGED; ALCOHOL CONSUMPTION; CLINICAL TRIAL; CONFERENCE PAPER; DIET; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; SELF REPORT;

EID: 0001696152     PISSN: 09540121     EISSN: None     Source Type: Journal    
DOI: 10.1080/09540120050042891     Document Type: Conference Paper

References (23)

1. BANGSBERG, D., TULSKY, J., HECHT, F. & MOSS, A. (1997). Protease inhibitors in the homeless [commentary]. Journal of the American Medical Association, 278, 63-64.
2. BANGSBERG, D.R., HECHT, F.M., CHARLEBOIS, E.C., ZOLOPA, A.R., HOLODNIY, M., SHEINER, L., CHESNEY, M.A. & MOSS, A.R. (1999). Spontaneous Adherence (ADH) Audits (SAA) predict viral suppression in the REACH cohort. 6th Conference on Retroviruses and Opportunistic Infections, Chicago.
3. BESCH, C.L. (1995). Compliance in clinical trials. AIDS, 9, 1-10.
4. CENTERS FOR DISEASE CONTROL (1997). Update: trends in AIDS incidence - United States, 1996. Morbidity & Mortality Weakly Report, 46, 861-867.
5. COHEN, S., KAMARCK, T. & MARMELSTEIN, R. (1983). A global measure of perceived stress. Journal of Health and Social Behavior, 24, 385-396.
6. DUNBAR-JACOB, J. (1990). Predictors of patient adherence: patient characteristics. In: S.A. SHUMAKER, E.B. SCHRON, J.K. ICKENE, C.T. PARKER, J.L. PROBSTFIELD & J.M. WOLLE (Eds), The handbook of health behavior change (p. 349). New York: Springer.
7. DUNBAR-JACOB, J. (1993). Contributions to patient adherence: is it time to share the blame? Health Psychology, 12, 91-92.
8. FOWLER, F.J. (1984). Survey research methods. Beverly Hills, CA: Sage.
9. HAYNES, R.B., TAYLOR, D.W. & SACKETT, D.L. (1979). Compliance in health care. Baltimore, MD: Johns Hopkins University Press.
10. HECHT, F.M., COLFAX, G., SWANSON, M. & CHESNEY, M.A. (1998a). Adherence and effectiveness of protease inhibitors in clinical practice. 5th Conference on Retroviruses and Opportunistic Infections, February 2-6, Chicago, Illinois.
11. HECHT, F.M., GRANT, R.M., PETROPOULOS, C.J. et al. (1998b). Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors [see comments]. New England Journal of Medicine, 339, 307-311.
12. ICKOVICS, J.R. & MEISLER, A. (1997). Adherence and retention in AIDS clinical trials: a framework for research and application. Journal of Clinical Epidemiology, 50, 385-391.
13. LEIGH, B. & STALL, R. (1993). Substance use and risky sexual behavior for exposure to HIV: issues in methodology, interpretation and prevention. American Psychologist, 48, 1035-1045.
14. MIROWSKY, J. & ROSS, C.E. (1992). Age and depression. Journal of Health and Social Behaviour, 33, 187-205.
15. MONTANER, J.S., REISS, P., COOPER, D. et al. (1998). A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial, Italy, The Netherlands, Canada and Australia Study [see comments]. Journal of the American Medical Association, 2791, 930-937.
16. NlEUWKERK, P.T., GISOLF, E.H., VAN LEEUWEN, R., DANNER, S.A., DE BOER, J.B., CHESNEY, M.A. & SPRANGERS, M.A.G. (1998). Self-reported adherence to ritonavir/saquinavir and ritonavir/saquinavir/stavudine in a randomized clinical trial: preliminary results. 12th World AIDS Conference, Abstract 32362, June 28-July 3 Geneva.
17. PALELLA, F.J., JR., DELANEY, K.M., MOORMAN, A.C. et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators [see comments]. New England Journal of Medicine, 338, 853-860.
18. PHARMACOLOGY COMMITTEE AND THE ADHERENCE AND RETENTION WORKING GROUP OF THE OUTCOMES COMMITTEE (1998). Measuring medication adherence in ACTG studies. Published by the NIH AIDS Clinical Trials Group.
19. SHELTON, M.J., ESCH, L.D., HEWITT, R.G., COUSINS, S. & MORSE G.D. (1998). The impact of patient-reported adherence with antiretroviral therapy on virologic response. 38th ICAAC meeting of the American Society for Microbiology, Abstract 1-170, September 24-27, San Diego, California.
20. URQUHART, J. (1991). Compliance and clinical trials. The Lancet, 337, 1224-1225.
21. VANHOVE, G.F., SHAPIRO, J.M., WINTERS, M.A., MERIGAN, T.C. & BLASCHKE, T.F. (1996). Patient compliance and drug failure in protease inhibitor monotherapy [letter]. Journal of the American Medical Association, 276, 1955-1956.
22. VENTURA, S.J., ANDERSON, R.N., MARTIN, J.A. & SMITH, B.L. (1998). Births and deaths: preliminary data for 1997. National Vital Statistics Report, 47, 1-41.
23. WAINBERG, M.A. & FRIEDLAND, G. (1998). Public health implications of antiretroviral therapy and HIV drug resistance. Journal of the American Medical Association, 279, 1977-1983.